Differential treatment outcomes in BRCA1/2-, CDK12-, and ATM-mutated metastatic castration-resistant prostate cancer.
Daniel H KwonJonathan ChouSteven M YipMelissa A ReimersLi ZhangFrancis WrightMallika S DhawanHala T BornoArpita DesaiRahul R AggarwalAlexander W WyattEric J SmallAjjai S AlvaKim N ChiFelix Y FengVadim S KoshkinPublished in: Cancer (2021)
Responses to standard therapies were generally superior in patients with BRCA1/2 mutations and inferior in patients with ATM or CDK12 mutations. The DDRm type did not independently predict OS. After progression on first-line abiraterone or enzalutamide, carboplatin-based chemotherapy was associated with the longest OS. These findings may inform treatment discussions and clinical trial design and require prospective validation.
Keyphrases
- clinical trial
- dna damage
- cell cycle
- prostate cancer
- dna repair
- dna damage response
- small cell lung cancer
- squamous cell carcinoma
- locally advanced
- breast cancer risk
- phase iii
- phase ii study
- randomized controlled trial
- cell proliferation
- oxidative stress
- study protocol
- combination therapy
- radiation therapy
- open label
- rectal cancer
- wild type